A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Advanced or Metastatic Solid Tumors With IDH Mutations

Grants and Contracts Details

StatusActive
Effective start/end date10/8/218/21/24

Funding

  • Syneos Health LLC: $90,387.00